Does Nexium (esomeprazole) cause side effects?
Nexium (esomeprazole) is a proton pump inhibitor (PPI) which block the production of acid by the stomach and are used to treat conditions such as stomach and duodenal ulcers, gastroesophageal reflux disease (GERD) and the Zollinger-Ellison syndrome which all are caused by stomach acid.
Nexium, like other proton-pump inhibitors, blocks the enzyme in the wall of the stomach that produces acid. By blocking the enzyme, the production of acid is decreased, and this allows the stomach and esophagus to heal. Nexium 24 hour is available over-the-counter (OTC) without a prescription.
Common side effects of Nexium include
Serious side effects of Nexium include
- abnormal heartbeat,
- muscle pain,
- leg cramps, and
- water retention occur infrequently.
Proton pump inhibitors may increase the risk of Clostridium difficile infection. High doses and long-term use (1 year or longer) may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine; reduced absorption of vitamin B12 (cyanocobalamin); low levels of magnesium (hypomagnesemia); and increased risk of heart attacks.
Drug interactions of Nexium include diazepam, because Nexium potentially can increase the concentration of diazepam in blood by decreasing the elimination of diazepam in the liver.
- The absorption of certain drugs may be affected by stomach acidity.
- Therefore, Nexium and other PPIs that reduce stomach acid also reduce the absorption and concentration in blood of ketoconazole and increase the absorption and concentration in blood of digoxin. This may lead to reduced effectiveness of ketoconazole or increased digoxin toxicity, respectively.
- Through unknown mechanisms, Nexium may increase blood levels of saquinavir and reduce blood levels of nelfinavir and atazanavir. Therefore, nelfinavir or atazanavir should not be administered with Nexium, and physicians should consider reducing the dose of saquinavir in order to avoid side effects from saquinavir.
- Clopidogrel is converted to its active form by enzymes in the liver. Nexium reduces the activity of these enzymes and potentially can reduce the activity of clopidogrel. Nexium should not be used with clopidogrel.
- Nexium increases the concentration of cilostazol and its metabolites. The dose of cilostazol should be reduced from 100 mg twice daily to 50 mg twice daily when given with esomeprazole. Nexium may increase blood levels of methotrexate and tacrolimus.
Use of Nexium in pregnant women has not been adequately evaluated. Nexium has not been adequately studied in nursing women. Consult your doctor before breastfeeding.
What are the important side effects of Nexium (esomeprazole)?
Esomeprazole, like other PPIs, is well-tolerated. The most common side effects are
Nervousness, abnormal heartbeat, muscle pain, weakness, leg cramps, and water retention occur infrequently.
Proton pump inhibitors may increase the risk of Clostridium difficile infection. High doses and long-term use (1 year or longer) may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine. Prolonged use also reduces absorption of vitamin B12 (cyanocobalamin).
Long-term use of PPIs has also been associated with low levels of magnesium (hypomagnesemia). Analysis of patients taking PPIs for long periods of time showed an increased risk of heart attacks.
Therefore, it is important to use the lowest doses and shortest duration of treatment necessary for the condition being treated.
Nexium (esomeprazole) side effects list for healthcare professionals
The following serious adverse reactions are described below and elsewhere in labeling:
- Acute Interstitial Nephritis
- Clostridium difficile-Associated Diarrhea
- Bone Fracture
- Cutaneous and Systemic Lupus Erythematosus
- Fundic Gland Polyps
Clinical Trials Experience With Intravenous Nexium
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of intravenous esomeprazole is based on results from clinical trials conducted in four different populations including patients having symptomatic GERD with or without a history of erosive esophagitis (n=199), patients with erosive esophagitis (n=160), healthy subjects (n=204) and patients with bleeding gastric or duodenal ulcers (n=375).
Symptomatic GERD And Erosive Esophagitis Trials
The data described below reflect exposure to Nexium I.V. for Injection in 359 patients. Nexium I.V. for Injection was studied only in actively-controlled trials. The population was
- 18 to 77 years of age;
- 45% Male, 52% Caucasian,
- 17% Black,
- 3% Asian,
- 28% Other, and
- had either
- erosive reflux esophagitis (44%) or
- GERD (56%).
Most patients received doses of either 20 or 40 mg either as an infusion or an injection. Adverse reactions occurring in ≥1% of patients treated with intravenous esomeprazole (n=359) in clinical trials are listed below:
Table 2: Adverse Reactions Occurring at an Incidence ≥ 1% in the Nexium I.V. Group
|Adverse Reactions||% of patients Esomeprazole Intravenous|
|Injection site reaction||1.7|
Intravenous treatment with esomeprazole 20 and 40 mg-administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of esomeprazole.
A randomized, open-label, multi-national study to evaluate the pharmacokinetics of repeated intravenous doses of once daily esomeprazole in pediatric patients 1 month to 17 years old, inclusive was performed. The safety results are consistent with the known safety profile of esomeprazole and no unexpected safety signals were identified.
Risk Reduction Of Rebleeding Of Gastric Or Duodenal Ulcers In Adults
The data described below reflect exposure to Nexium I.V. for Injection in 375 patients. Nexium I.V. for Injection was studied in a placebo-controlled trial. Patients were randomized to receive Nexium I.V. for Injection (n=375) or placebo (n=389). The population was 18 to 98 years old; 68% Male, 87% Caucasian, 1% Black, 7% Asian, 4% other, who presented with endoscopically confirmed gastric or duodenal ulcer bleeding.
Following endoscopic hemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for a total treatment duration of 72 hours. After the initial 72-hour period, all patients received oral proton pump inhibitor (PPI) for 27 days.
Table 3: Incidence (%) of Adverse Reactions that Occurred in Greater than 1 % of Patients within 72 Hours after Start of Treatment1
|Number (%) of patients|
|Duodenal ulcer hemorrhage||16 (4.3%)||16 (4.1%)|
|Injection site reaction2||16 (4.3%)||2 (0.5%)|
|Pyrexia||13 (3.5%)||11 (2.8%)|
|Cough||4 (1.1%)||1 (0.3%)|
|Dizziness||4 (1.1%)||3 (0.8%)|
|1 Incidence ≥1% in the esomeprazole group and greater than placebo group safety population|
2 Injection site reactions included erythema, swelling, inflammation, pruritus, phlebitis, thrombophlebitis and superficial phlebitis.
With the exception of injection site reactions described above, intravenous treatment with esomeprazole administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of esomeprazole.
The following adverse reactions have been identified during post-approval use of Nexium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Postmarketing Reports - There have been spontaneous reports of adverse events with postmarketing use of esomeprazole. These reports occurred rarely and are listed below by body system:
- Blood And Lymphatic System Disorders: agranulocytosis, pancytopenia;
- Eye Disorders: blurred vision;
- Gastrointestinal Disorders: pancreatitis; stomatitis; microscopic colitis; fundic gland polyps;
- Hepatobiliary Disorders: hepatic failure, hepatitis with or without jaundice;
- Immune System Disorders: anaphylactic reaction/shock; systemic lupus erythematosus;
- Infections and Infestations: GI candidiasis;
- Metabolism and nutritional disorders: hypomagnesemia with or without hypocalcemia and/or hypokalemia;
- Musculoskeletal And Connective Tissue Disorders: muscular weakness, myalgia, bone fracture;
- Nervous System Disorders: hepatic encephalopathy, taste disturbance;
- Psychiatric Disorders: aggression, agitation, depression, hallucination;
- Renal and Urinary Disorders: interstitial nephritis;
- Reproductive System and Breast Disorders: gynecomastia;
- Respiratory, Thoracic and Mediastinal Disorders: bronchospasm;
- Skin and Subcutaneous Tissue Disorders: alopecia, erythema multiforme, hyperhidrosis, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN, some fatal), cutaneous lupus erythematosus.
Other adverse events not observed with Nexium, but occurring with omeprazole can be found in the omeprazole package insert, Adverse Reactions section.
What drugs interact with Nexium (esomeprazole)?
- Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.
- In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.
- Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
- Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
- Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
- Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
- Co-administration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam. Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.
- However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.
- Clopidogrel is metabolized to its active metabolite in part by CYP2C19.
- Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of Nexium I.V. with clopidogrel.
- When using Nexium I.V., consider use of alternative anti-platelet therapy.
- Omeprazole acts as an inhibitor of CYP2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased Cmax and AUC of cilostazol by 18% and 26%, respectively.
- Cmax and AUC of one of its active metabolites, 3,4-dihydro-cilostazol, which has 4-7 times the activity of cilostazol, were increased by 29% and 69%, respectively.
- Co-administration of cilostazol with esomeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite. Therefore, a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered.
- Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. Dose adjustment of esomeprazole is not normally required for the recommended doses. However, in patients who may require higher doses, dose adjustment may be considered.
- Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased esomeprazole serum levels. Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with St. John's Wort, an inducer of CYP3A4. In a cross-over study in 12 healthy male subjects, St. John's Wort (300 mg three times daily for 14 days) significantly decreased the systemic exposure of omeprazole in CYP2C19 poor metabolizers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolizers (Cmax and AUC decreased by 49.6% and 43.9%, respectively). Avoid concomitant use of St. John's Wort or rifampin with Nexium.
- Co-administration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
- Concomitant use of atazanavir and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.
- Omeprazole has been reported to interact with some antiretroviral drugs.
- The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19.
- For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole.
- Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75%, respectively, for nelfinavir and M8.
- Following multiple doses of atazanavir (400 mg daily) and omeprazole (40 mg daily, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.
- Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.
- For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15.
- Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.
- Studies evaluating concomitant administration of esomeprazole and either naproxen (non-selective NSAID) or rofecoxib (COX-2 selective NSAID) did not identify any clinically relevant changes in the pharmacokinetic profiles of esomeprazole or these NSAIDs.
- Due to its effects on gastric acid secretion, esomeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability.
- Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole. Esomeprazole is an enantiomer of omeprazole.
- Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects).
- Co-administration of digoxin with Nexium I.V. is expected to increase the systemic exposure of digoxin. Therefore, patients may need to be monitored when digoxin is taken concomitantly with Nexium I.V.
- Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.
- The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving Nexium I.V. and MMF.
- Use Nexium I.V. with caution in transplant patients receiving MMF.
Interactions With Investigations Of Neuroendocrine Tumors
- Drug-induced decrease in gastric acidity results in enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors.
- Concomitant administration of esomeprazole and tacrolimus may increase the serum levels of tacrolimus.
- Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.
Nexium (esomeprazole) is a proton pump inhibitor (PPI) which block the production of acid by the stomach and are used to treat conditions such as stomach and duodenal ulcers, gastroesophageal reflux disease (GERD) and the Zollinger-Ellison syndrome which all are caused by stomach acid. Common side effects of Nexium include diarrhea, nausea, vomiting, headaches, rash and dizziness. Use of Nexium in pregnant women has not been adequately evaluated. Nexium has not been adequately studied in nursing women.
Multimedia: Slideshows, Images & Quizzes
Acid Reflux (Heartburn, GERD): Symptoms & Remedies
Heartburn is a symptom of acid reflux that causes chest pain when stomach acid backs up into the esophagus. Heartburn symptoms...
Ulcerative Colitis: Symptoms, Diet, Treatment, Causes
Ulcerative Colitis is a form of inflammatory bowel disease and is slightly different than Crohn's disease. Learn the causes,...
Digestive Disorders: Visual Guide to Stomach Ulcers
Learn about the causes and symptoms of stomach ulcers, and find out which kinds of treatment can help.
Ulcerative Colitis Quiz: Diet, Symptoms & Treatment
What is ulcerative colitis and what risks are associated with suffering over the long term? Take this Ulcerative Colitis Quiz to...
GERD Quiz: Test Your Digestive Diseases IQ
Who is at risk for developing GERD? Are you? Take this quiz to learn what GERD is, if you're at risk, and what you can do about...
Picture of Peptic Ulcer
A hole in the lining of the stomach, duodenum, or esophagus. See a picture of Peptic Ulcer and learn more about the health topic.
Related Disease Conditions
GERD (Acid Reflux, Heartburn)
Gastroesophageal reflux disease (GERD), also called acid reflux, can cause symptoms like heartburn, chest pain, regurgitation, and nausea. Learn about causes, diagnosis, treatment and prevention.
Peptic Ulcer (Stomach Ulcer)
Peptic or stomach ulcers are ulcers in the lining of the stomach, duodenum, or esophagus. Learn about symptoms, causes, diet, and treatment.
Ulcerative Colitis Diet Plan
An ulcerative colitis diet plan can help a person with the disease avoid foods and drinks that trigger flares. There also are foods that can soothe ulcerative colitis symptoms during a flare. Types of ulcerative colitis plans include a high-calorie diet, a lactose-free diet, a low-fat diet, a low-fiber diet (low-residue diet), or a low-salt diet. Self-management of ulcerative colitis using healthy lifestyle habits and a nutrient rich diet can be effective in management of the disease. Learn what foods to avoid that aggravate, and what foods help symptoms of the disease and increase bowel inflammation.
Ulcerative colitis is a chronic inflammation of the colon. Symptoms and signs include abdominal pain, diarrhea, and rectal bleeding. Ulcerative colitis is closely related to Crohn's disease, and together they are referred to as inflammatory bowel disease. Treatment depends upon the type of ulcerative colitis diagnosed.
Crohn's Disease vs. Ulcerative Colitis
Crohn's disease and ulcerative colitis are diseases that cause inflammation of part of or the entire digestive tract (GI). Crohn's affects the entire GI tract (from the mouth to the anus), while ulcerative colitis or ulcerative colitis only affects the large and small intestine and ilium. Researchers do not know the exact cause of either disease. About 20% of people with Crohn's disease also have a family member with the disease. Researchers believe that certain factors may play a role in causing UC. Both Crohn's disease and ulcerative colitis are a type of inflammatory bowel disease or IBD. Crohn's disease and ulcerative colitis both have similar symptoms and signs, for example, nausea, loss of appetite, fatigue, weight loss, episodic and/or persistent diarrhea, fever, abdominal pain and cramping, rectal bleeding, bloody stools, joint pain and soreness, eye redness, or pain. Symptoms unique to Crohn’s disease include anemia and skin changes. Symptoms of unique to ulcerative colitis include certain rashes, and an urgency to defecate (have a bowel movement). Doctors diagnose both diseases with similar tests and procedures. While there is no cure for either disease, doctors and other health care professionals can help you treat disease flares, and manage your Crohn's or ulcerative colitis with medication, diet, nutritional supplements, and/or surgery.
Nonsteroidal Anti-inflammatory Drugs and Ulcers
Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed medications for the treatment of inflammatory conditions. Examples of NSAIDs include aspirin, ibuprofen, naproxen, and more. One common side effect of NSAIDs is peptic ulcer (ulcers of the esophagus, stomach, or duodenum). Side effects, drug interactions, warnings and precautions, and patient safety information should be reviewed prior to taking NSAIDs.
What Is the Life Expectancy of Someone With Ulcerative Colitis?
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that affects the inner lining of the large intestine (large bowel) leading to erosion and ulcers. It is a lifelong illness with no specific cause or cure.
GERD (Acid Reflux) in Infants and Children
GERD (gastroesophageal reflux disease) is the upward movement of stomach content, including acid, into the esophagus and sometimes into or out of the mouth. Common symptoms of GERD in children include colic, feeding problems, poor growth, frequent vomiting or coughing, heartburn, regurgitation, recurrent wheezing, pneumonia, choking, or gagging. Treatment may involve elevating the child's bed, keeping the child upright after eating, limiting foods that seem to make the reflux worse, encouraging your child to exercise, and serving several small meals a day.
Is Ulcerative Colitis Curable?
Ulcerative colitis is an inflammatory bowel disease (IBD) that affects the inner lining of the large intestine (large bowel or colon) leading to erosion and ulcers. It is also associated with various manifestations outside of the colon, such as inflammation of the eyes, joints, skin, and lungs. Ulcerative colitis is a lifelong illness with no specific cause or cure. Patients have repeated cycles of flare-ups and disappearance of the disease.
How Do You Know if You Have a Stomach Ulcer?
Stomach ulcer or gastric ulcer is a painful open sore that develops on the lining of your stomach due to the damage to the inner stomach lining. This is a type of peptic ulcer disease. Stomach ulcers often can be easily cured; however, it can be fatal if not treated properly. It occurs mostly in men are than in women.
Peptic Ulcer Disease
Peptic ulcers are sores that develop on the inner lining of your stomach and the upper portion of your small bowel (duodenum). Peptic ulcers cause symptoms like heartburn, nausea, vomiting, weight loss and other symptoms. Ulcers are treated with lifestyle modification and medications.
Can Ulcerative Colitis Be Cured With Surgery?
Ulcerative colitis is a chronic inflammatory condition of the colon (the large bowel) characterized by frequent bloody diarrhea (10-30 episodes) throughout the day. Medicines can only reduce the intensity of its symptoms and surgery is the only option to cure it.
How Serious Is Ulcerative Colitis?
Ulcerative colitis (UC) is a lifelong disease with constant periods of flare-ups and remissions (periods without symptoms, which may last for weeks or years). Presently, there is no permanent medical cure for it, but there are various medications that can provide symptomatic relief, reduce inflammation and manage flare-ups.
Treatment & Diagnosis
- GERD Gastroesophageal Reflux Disease FAQs
- Ulcerative Colitis FAQs
- Ulcers May Be Caused By Your Cat
- GERD: Types of antacids for GERD?
- GERD: Safe GERD medications for pregnancy?
- GERD Acid reflux during pregnancy?
- GERD Symptoms improve with weight loss?
- Why is acid reflux GERD worse at night time?
- GERD Symptoms After Exercise?
- Bad breath from GERD?
- GERD Best treatment for Barrett Esophagus?
- GERD How long can you take Prilosec safely?
- GERD: Use of Propulsid GERD
- GERD Surgery - No Good?
- GERD: Questions To Ask Your Doctor About GERD (Heartburn)
- GERD Surgery Doesn't Prevent Cancer
- Ulcers: What Causes Ulcers?
- Can H. Pylori Ulcer Pain Continue After Treatment?
- Does Aspirin Make Ulcers Worse?
- What Is the Relationship Between GERD and Scleroderma?
- Does Stress Cause Ulcerative Colitis?
- Does IBS Cause Crohn's Disease or Ulcerative Colitis?
- Does Stress Cause Ulcers?
- Bleeding Ulcer Symptoms and Causes
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.